Marker Therapeutics, Inc. (NASDAQ:MRKR) Major Shareholder Buys $1,773,600.00 in Stock

Marker Therapeutics, Inc. (NASDAQ:MRKR) major shareholder Enterprise Associates 16 New bought 554,250 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the acquisition, the insider now directly owns 1,625,678 shares in the company, valued at $5,202,169.60. This represents a 51.73 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Marker Therapeutics Price Performance

NASDAQ:MRKR opened at $3.38 on Thursday. The business’s 50-day simple moving average is $3.71 and its two-hundred day simple moving average is $3.83. Marker Therapeutics, Inc. has a 52 week low of $2.44 and a 52 week high of $6.16.

Institutional Trading of Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. Invst LLC acquired a new stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned about 0.22% of Marker Therapeutics at the end of the most recent reporting period. Institutional investors own 22.39% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH increased their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.